Categories: HealthcareNews

DuPont Schedules Third Quarter 2025 Earnings Conference Call

WILMINGTON, Del., Oct. 20, 2025 /PRNewswire/ — DuPont (NYSE: DD) will release its third quarter financial results at 6:00 a.m. ET on Thursday, November 6, 2025. In addition, the company will host a conference call at 8:00 a.m. ET that day.

The event will be webcast live and can be accessed on DuPont’s Investors Relations webpage. A replay, along with the earnings release and supporting materials, will also be posted to the website.

The dial-in number for the conference call is 888-440-4172 toll-free within the U.S. or +1-646-960-0673. The conference ID is 5994046.

DuPont will reflect the previously announced divestiture of its Aramids business as discontinued operations beginning with third quarter 2025 reporting and will reflect its electronics business, Qnity, as discontinued operations beginning in fourth quarter 2025 reporting following the intended separation of Qnity on November 1, 2025.

Qnity expects to provide a business update on a separate conference call to be announced at a later date.

About DuPont
DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

DuPontTM and all products, unless otherwise noted, denoted with TM, SMor ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dupont-schedules-third-quarter-2025-earnings-conference-call-302587880.html

SOURCE DuPont

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

8 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

11 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

11 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

11 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

11 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

11 hours ago